In the company’s initial announcement, Cal Yee Farms said the products were recalled “after an FDA inspection of our facility.” “People who have an allergy or severe sensitivity to milk ...

In a letter to FDA Deputy Commissioner for Human Foods ... wrote that shifting funds away from the Office of Inspections and Investigation would slash resources available to state and local ...

Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "FDA Inspections: From Site Preparation to Response" training has been added to ResearchAndMarkets.com's offering. This is a practical, hands-on two-day ...

A U.S. subsidiary of generic drugmaker Laurus Labs has been issued a Form 483 with one observation by the U.S. Food and Drug Administration (U.S. FDA) after a post-marketing adverse drug ...

In response to a report from the Government Accountability Office, the FDA says the biggest stumbling block to conducting inspections of food facilities is understaffing. The Food and Drug ...

C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...

advertisement 1. KNOW THE MARKING SCHEME Most of us are eager to launch into a ground-plan, but it is a must to clearly understand the marking scheme.Here's a quick refresher: +4 marks for a correct ...

Not all chemical hair relaxers include the chemical, but many include ingredients that can release formaldehyde when heated, the FDA said in 2024. Over the years, an increasing number of studies ...

However, it had to be used in conjunction with an oral medication. The FDA has now expanded its approval to include the standalone use of the nasal spray for adults with treatment-resistant major ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.